PharmAthene Updates Status Of SparVax Anthrax Vaccine Contract

April 7, 2014 PharmAthene, Inc. announced today that it has received notice from the Department of Health and Human Services (HHS), Biomedical Advanced Research and Development Authority (BARDA), advising the Company of its decision to de-scope the current SparVax® anthrax vaccine contract through a partial termination for convenience.  BARDA will provide additional guidance to PharmAthene on the contractual changes, following which …

BiondVax Meets with the US Biomedical Advanced Research and Development Authority (BARDA) to Present the Use of its Universal Flu Vaccine

BiondVax Pharmaceuticals Ltd, developer of a universal flu vaccine, announced today that the Company has just returned from a meeting with officials at the Biomedical Advanced Research and Development Authority/Health and Human Services (BARDA/HHS) at which clinical trial results for BiondVax’s universal flu vaccine, the Multimeric 001, was presented. BiondVax was invited to give this seminar to the Influenza Division at BARDA, …